Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris
Status:
Completed
Trial end date:
2016-04-27
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the pharmacokinetics of luliconazole cream 1%, as
measured by circulating plasma levels of luliconazole, when maximal quantity of luliconazole
cream 1% is applied to participants of 12 years to less than (<) 18 years of age with
moderate to severe inter-digital tinea pedis or tinea cruris.
Phase:
Phase 4
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.